Teclistamab treat

Phase 1

WWest China Hospital

Teclistamab treat is one of 15 therapeutic programs targeting Kidney. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

KidneyNot yet recruiting

KidneyPhase 1

Not yet recruiting

Competition

Competitive Landscape

19 competitors in Kidney

#DrugCompanyPhaseTrials

Nulojix

Bristol-Myers Squibb

Approved

5 2

Prevymis

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Approved

1 3

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 4

Trimethoprim-Sulfamethoxazole

Astellas

Phase 3

1 5

Fludara

Sanofi

Phase 1

1 6

Actemra

Roche

Preclinical

2 7

Imlifidase

HHansa Biopharma AB

Phase 2

1 8

Imuran

LLegacy Health System

Preclinical

1 9

Glucagon

XXeris Pharmaceuticals

Preclinical

1 10

Glypressin

MMallinckrodt

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Kidney

NCT07706205

Clinical

Trials by Indication[1]

Kidney1 trial

Safety and Efficacy of the Bispecific T-Cell Engager (BiTE) as Conditioning Regimen for ABO-incompatible Living Donor Kidney Transplantation

Not yet recruiting·WWest China Hospital·Phase 1·NCT07706205·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Teclistamab treat. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Teclistamab treat. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — West China Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: WWest China Hospital

Teclistamab treat

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Kidney1 trial

References

Drug Info

Quick Facts

Related News